Literature DB >> 31208953

How sustainable are new treatment strategies for NSCLC?

Jordi Remon1, Gilberto Lopes2, Carlos Camps3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31208953     DOI： 10.1016/S2213-2600(19)30184-5

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  3 in total

Review 1.  Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Authors:  Kartik Sehgal; Daniel B Costa; Deepa Rangachari
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

2.  Isovalerylspiramycin I suppresses non-small cell lung carcinoma growth through ROS-mediated inhibition of PI3K/AKT signaling pathway.

Authors:  Zeyu Liu; Moli Huang; Yue Hong; Shaoyang Wang; Yongle Xu; Cheng Zhong; Jingyuan Zhang; Zhengping Zhuang; Shan Shan; Tao Ren
Journal:  Int J Biol Sci       Date:  2022-05-21       Impact factor: 10.750

3.  Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.

Authors:  Bora Youn; Ira B Wilson; Vincent Mor; Nikolaos A Trikalinos; Issa J Dahabreh
Journal:  Health Serv Res       Date:  2021-03-07       Impact factor: 3.734
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.